NZ598758A - N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer - Google Patents

N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Info

Publication number
NZ598758A
NZ598758A NZ598758A NZ59875810A NZ598758A NZ 598758 A NZ598758 A NZ 598758A NZ 598758 A NZ598758 A NZ 598758A NZ 59875810 A NZ59875810 A NZ 59875810A NZ 598758 A NZ598758 A NZ 598758A
Authority
NZ
New Zealand
Prior art keywords
treatment
phthalazinamine
pyridinyl
pyrimidinyl
thienyl
Prior art date
Application number
NZ598758A
Other languages
English (en)
Inventor
Richard Kendall
Marc Payton
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NZ598758A publication Critical patent/NZ598758A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ598758A 2009-09-11 2010-09-09 N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer NZ598758A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
NZ598758A true NZ598758A (en) 2013-12-20

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598758A NZ598758A (en) 2009-09-11 2010-09-09 N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Country Status (34)

Country Link
US (1) US20120028917A1 (cg-RX-API-DMAC7.html)
EP (2) EP2818170B1 (cg-RX-API-DMAC7.html)
JP (1) JP5851403B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120082896A (cg-RX-API-DMAC7.html)
CN (1) CN102869361A (cg-RX-API-DMAC7.html)
AU (1) AU2010292225C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008325A2 (cg-RX-API-DMAC7.html)
CA (1) CA2773838C (cg-RX-API-DMAC7.html)
CL (1) CL2012000640A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120171A (cg-RX-API-DMAC7.html)
DK (1) DK2475368T3 (cg-RX-API-DMAC7.html)
EA (1) EA020526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2528485T3 (cg-RX-API-DMAC7.html)
HK (1) HK1205457A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150104T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024568T2 (cg-RX-API-DMAC7.html)
IL (1) IL218569A0 (cg-RX-API-DMAC7.html)
MA (1) MA33658B1 (cg-RX-API-DMAC7.html)
ME (1) ME02048B (cg-RX-API-DMAC7.html)
MX (1) MX2012003041A (cg-RX-API-DMAC7.html)
NZ (1) NZ598758A (cg-RX-API-DMAC7.html)
PE (1) PE20120895A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500504A1 (cg-RX-API-DMAC7.html)
PL (1) PL2475368T3 (cg-RX-API-DMAC7.html)
PT (1) PT2475368E (cg-RX-API-DMAC7.html)
RS (1) RS53807B1 (cg-RX-API-DMAC7.html)
SG (1) SG179102A1 (cg-RX-API-DMAC7.html)
SI (1) SI2475368T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500028B (cg-RX-API-DMAC7.html)
TN (1) TN2012000110A1 (cg-RX-API-DMAC7.html)
TW (1) TW201121956A (cg-RX-API-DMAC7.html)
UA (1) UA107675C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011031842A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202472B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201604517WA (en) 2013-12-03 2016-07-28 Amgen Inc Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
WO2017181087A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) * 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
HK1173655A1 (en) 2013-05-24
ZA201202472B (en) 2012-12-27
US20120028917A1 (en) 2012-02-02
CA2773838C (en) 2016-05-31
HRP20150104T1 (xx) 2015-03-13
EP2818170B1 (en) 2018-12-05
MX2012003041A (es) 2012-06-27
PL2475368T3 (pl) 2015-05-29
KR20120082896A (ko) 2012-07-24
EA020526B1 (ru) 2014-11-28
PT2475368E (pt) 2015-02-10
AU2010292225B2 (en) 2012-12-13
CL2012000640A1 (es) 2012-09-21
CR20120171A (es) 2012-08-09
EP2818170A1 (en) 2014-12-31
SMT201500028B (it) 2015-03-05
HK1205457A1 (en) 2015-12-18
EA201270383A1 (ru) 2013-04-30
MA33658B1 (fr) 2012-10-01
AU2010292225C1 (en) 2013-06-27
CA2773838A1 (en) 2011-03-17
ES2528485T3 (es) 2015-02-10
WO2011031842A1 (en) 2011-03-17
ME02048B (me) 2015-05-20
EP2475368B1 (en) 2014-12-17
IL218569A0 (en) 2012-05-31
AU2010292225A1 (en) 2012-04-12
DK2475368T3 (en) 2015-03-09
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
HUE024568T2 (hu) 2016-02-29
JP5851403B2 (ja) 2016-02-03
CN102869361A (zh) 2013-01-09
UA107675C2 (xx) 2015-02-10
JP2013504582A (ja) 2013-02-07
TN2012000110A1 (en) 2013-09-19
RS53807B1 (sr) 2015-06-30
PH12012500504A1 (en) 2015-04-29
TW201121956A (en) 2011-07-01
SG179102A1 (en) 2012-04-27
PE20120895A1 (es) 2012-08-19
BR112012008325A2 (pt) 2017-08-29

Similar Documents

Publication Publication Date Title
TN2012000110A1 (en) N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
WO2008089388A3 (en) Treatment of cancers having resistance to chemotherapeutic agents
PH12013500265A1 (en) Pharmaceutically active compounds as axl inhibitors
MX2010003668A (es) Derivados de purina sustituidas con primidina.
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
UY32251A (es) Compuestos quimicos
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
MA31358B1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2009155121A3 (en) Inhibitors of pi3 kinase
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2014015158A (es) Derivados de piridinona y piridazinona.
IN2014DN08582A (cg-RX-API-DMAC7.html)
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
JP2014532063A5 (cg-RX-API-DMAC7.html)
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
PH12012501476A1 (en) Aminoquinoline derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 SEP 2017 BY CPA GLOBAL

Effective date: 20140731

LAPS Patent lapsed